文献速递放疗物理与技术姑息放疗与转移瘤

美国五大商业保险对先进放疗技术的覆盖与ASTRO模型政策的一致性比较

Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies.
PubMed 文献 · Pract Radiat Oncol · 2019-08-22

本研究将ASTRO发布的IMRT、SRS、SABR和PBT模型政策与Aetna、Anthem、Cigna、Humana和United Healthcare五大商业保险公司的覆盖政策进行对比,计算各技术的一致性。

要点

  • 五大保险公司均覆盖CNS、头颈、肝胆胰、肛管和前列腺癌的IMRT。
  • SABR覆盖一致性最低(58.4%),PBT仅41.8%,差异有统计学意义。
  • ASTRO列出4种PBT场景无任何保险公司覆盖,需持续对话。

核心结论

  • 五大商业保险对IMRT、SRS、SABR和PBT的覆盖政策与ASTRO模型政策存在差异,PBT一致性最低。

研究设计与样本

  • 从最新ASTRO模型政策和5家保险公司2019版覆盖政策中提取IMRT、SRS、SABR、PBT按疾病部位的适宜指征,计算各技术的一致性。

主要发现

  • 所有5家保险公司均支持CNS、头颈、肝胆胰、肛管和前列腺癌的IMRT,腹膜后肿瘤无覆盖,膀胱癌仅1家覆盖。
  • 所有保险公司均覆盖良性脑肿瘤、脑转移、动静脉畸形和三叉神经痛的SRS,但均未覆盖药物难治性癫痫的SRS。
  • 所有保险公司均覆盖原发性肝癌、肺癌及低/中危前列腺癌的SABR,但均未覆盖原发性胆道肿瘤的SABR。
  • 仅1家保险公司覆盖原发性/转移性肾上腺疾病和原发性肾癌的SABR。
  • 所有保险公司均批准眼黑色素瘤、颅底肿瘤和儿童恶性肿瘤的PBT,但ASTRO列出的脊柱疾病、腹膜后肉瘤、头颈肿瘤和遗传性放射敏感综合征4种PBT场景无任何保险公司覆盖。

临床怎么用

  • 临床医生在申请先进放疗技术前应了解保险覆盖差异,对PBT等低一致性技术需提前准备应对策略。

局限性

  • 仅纳入5家最大公开商业保险公司的2019版政策,未涵盖其他支付方或更新政策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to compare and contrast the American Society for Radiation Oncology (ASTRO) model policies (MPs) for intensity modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), stereotactic ablative radiation therapy (SABR), and proton beam therapy (PBT) with the coverage policies constructed by 5 of the largest publicly available commercial insurers throughout the United States (ie, Aetna, Anthem, Cigna, Humana, and United Healthcare). METHODS AND MATERIALS: Appropriate indications for IMRT, SRS, SABR, and PBT by disease site (and particular clinical setting thereof) were extracted from the most recently published ASTRO MPs and published coverage policies (2019 editions) of the 5 carriers. After tabulation, concordance between ASTRO MPs and insurance policies were calculated for each modality. RESULTS: All 5 insurer policies supported IMRT for neoplasms of the central nervous system, head/neck, hepatopancreaticobiliary, anal, and prostate cancers. The least covered diseases were retroperitoneal tumors (n = 0 carriers) and bladder cancer (n = 1). For SRS, all carriers covered benign brain tumors, brain metastases, arteriovenous malformations, and trigeminal neuralgia. None of the insurance carriers covered SRS for medically refractory epilepsy. For SABR, primary liver, lung, and low- or intermediate-risk prostate cancer were covered by all insurers, and none allowed SABR for primary biliary neoplasms. Only one insurance carrier each covered SABR for primary/metastatic adrenal disease and primary renal cancer. All carriers approved PBT for ocular melanoma, skull base tumors, and pediatric malignancies. The ASTRO MPs listed 4 PBT scenarios (ie, spinal disease, retroperitoneal sarcoma, head/neck neoplasms, and patients with genetic radiosensitivity syndromes) not covered by any insurer. Concordance between insurance carriers and ASTRO MPs was 67.8% for IMRT, 72.0% for SRS, 58.4% for SABR, and 41.8% for PBT (P = .005). CONCLUSIONS: Coverage guidelines for IMRT, SRS, SABR, and PBT vary across 5 major insurance providers and may be substantially discordant compared with ASTRO coverage guidelines. There remain several specific areas where ongoing and future dialogues between ASTRO members, payers, and policymakers remain essential.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Verma V, Ludmir EB, Mesko SM, et al. Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. Pract Radiat Oncol. 2019. PMID: 31446147. doi:10.1016/j.prro.2019.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。